Table 2.

Synergy (σ_50%) in blocking the infection of Tzm-bl cells by R5 and X4 HIV-1 isolates and clones

Combination	Virus
	R5				X4
	CC1/85	9-6	9-7	9-8	IIIB	LAI	NL4.3
VCV + PRO 140	0.35a±0.075 (n=5)	0.33±0.035 (n=7)	0.35±0.045 (n=4)	0.58±0.27 (n=4)	-	-	-
VCV/AMD3100b + T-20	0.22±0.023 (n=4)	0.68±0.066 (n=8)	0.84±0.062 (n=5)	0.84±0.075 (n=6)	1.2±0.23 (n=8)	0.90±0.141 (n=6)	1.1±0.094 (n=7)
VCV/AMD3100b + Nevirapinec	0.58±0.099 (n=3)	0.93±0.10 (n=3)	0.87±0.058 (n=3)	0.85±0.036 (n=3)	1.6±0.27 (n=4)	1.3±0.30 (n=3)	1.1±0.14 (n=3)
CD4-IgG2 + 17b	1.1±0.23 (n=4)	0.62±0.16 (n=4)	0.78±0.16 (n=6)	0.73±0.12 (n=5)	1.1±0.14 (n=4)	1.2±0.18 (n=3)	0.79±0.099 (n=5)
b12 + 2G12	0.88±0.12 (n=4)	0.72±0.066 (n=3)	0.60±0.038 (n=5)	0.75±0.051 (n=4)	0.77±0.13 (n=3)	0.66±0.033 (n=3)	0.85±0.081 (n=4)
b12 + 2F5	0.73±0.16 (n=3)	1.1±0.050 (n=3)	1.6±0.39 (n=3)	0.71±0.12 (n=4)	0.95±0.065 (n=3)	0.75±0.014 (n=3)	1.2±0.17 (n=3)
b12 + 17b	0.68±0.15 (n=3)	1.5±0.12 (n=4)	1.2±0.289 (n=4)	1.9±0.28 (n=3)	1.2±0.21 (n=4)	0.93±0.066 (n=3)	0.69±0.10 (n=3)
2G12 + 2F5	0.50±0.094 (n=3)	1.6±0.78 (n=3)	0.69±0.141 (n=3)	0.60±0.055 (n=3)	0.67±0.16 (n=3)	0.60±0.17 (n=3)	1.00±0.105 (n=3)
2G12 + 17b	0.64±0.049 (n=8)	1.2±0.13 (n=7)	0.78±0.097 (n=6)	0.80±0.063 (n=9)	0.53±0.12 (n=7)	0.72±0.11 (n=7)	1.2±0.16 (n=8)
2F5 + 17b	1.4±0.50 (n=6)	1.6±0.47 (n=6)	1.1±0.28 (n=5)	0.83±0.20 (n=6)	0.65±0.19 (n=4)	0.50±0.050 (n=4)	0.98±0.125 (n=4)

^aThe values are the mean values of σ_50%from n (3 ≤ n ≤ 9) replicate experiments± SEM. σ_50% denotes synergy when <1, additivity when = 1, and antagonism when >1. Mean σ_50% values − 2 SEM >1 are shown in underlined italics; mean σ_50% values + 2 SEM < 1 are in bold. Values marked thus indicate synergy or antagonism ascertained with 95% confidence.

^bVCV was used against R5 viruses, AMD3100 against X4 viruses.

^cNevirapine is an NNRTI and thus the only inhibitor tested that blocks a post-entry step.